The traditional textbook account of metabolic regulation describes a set of well-characterized organ-specific responses: pancreatic insulin secretion, hepatic glucose handling, adipose lipid storage, skeletal-muscle glucose disposal. The systems biology era has reframed this picture: rather than discrete organ responses, metabolic adaptation is now understood as a coordinated network response orchestrated by inter-organ signaling factors, of which insulin and glucagon are merely the best-characterized examples.
Multi-omics studies of metabolic challenge — caloric restriction, exercise, GLP-1RA administration, fasting — have revealed dozens of additional signaling axes that participate in the integrated response. FGF21 from liver and brown adipose tissue. Asprosin from white adipose. GDF15 from a wide range of stress-responsive cells. The mitochondrial-derived peptide family. Lactate as a metabolic signaling molecule beyond its glycolytic-output role. The picture that emerges is of a richly interconnected endocrine network in which tissue-specific responses are coordinated through circulating signals to maintain organism-level metabolic homeostasis.
The therapeutic implication is that effective metabolic intervention often requires engagement of multiple nodes in this network rather than maximal stimulation of a single target. The progression from selective GLP-1 agonism to dual GLP-1/GIP agonism to triple GLP-1/GIP/glucagon agonism in the cardiometabolic space mirrors this systems-level understanding. Future generations of metabolic therapeutics are likely to be polypharmacological by design, engaging coordinated subsets of the inter-organ signaling network rather than maximizing affinity at any single receptor.